The domestic pig as a model for evaluating olestra's nutritional effects.
Experimental conditions for measuring the effect of the noncaloric fat substitute olestra on the availability of dietary nutrients were established in the weanling domestic pig. To evaluate the tolerance of the pig for dietary fat levels similar to those in the human diet, groups were fed a standard corn-soy-based swine feed with and without 14% (30% of energy) added fat for 4 wk. To evaluate the adequacy of a purified diet to produce good growth, groups of pigs were fed purified diets providing 30% of energy from fat and micronutrients at 1, 1.3 or 1.6 times the NRC's requirements for 5- to 10-kg swine. Cumulative body weight gain, digestible feed efficiency and a lack of adverse effects showed that the pig can tolerate diets providing 30% of energy from fat and that a purified diet providing the NRC's requirements for micronutrients produces growth comparable to a nutritionally complete swine feed. To determine whether tissue concentrations of vitamins A, D, E and K in the pig respond to olestra and dietary concentrations of the vitamins, two groups were fed purified diet providing 1 or 1.6 times the NRC's requirements for micronutrients and 4.8% olestra. Significant increases occurred in the serum concentration of 25-hydroxyergocalciferol and liver concentrations of retinol and alpha-tocopherol with increasing dietary concentrations of the vitamins. Olestra reduced the tissue concentrations of vitamins A, D and E. Prothrombin time was not affected by dietary concentration of either phylloquinone or olestra. To determine the amount of UV light exposure required to produce 50-80% of vitamin D status from vitamin D3, a range typical of humans, two groups of pigs were fed the NRC requirement for vitamin D and exposed to 15 or 45 min/d of UV light. Serum concentration of 25-hydroxycholecalciferol increased with increased exposure time. UV exposure of 1-2 min/d was calculated to be sufficient to produce 50-80% of total vitamin D status from vitamin D3. No antemortem observations indicated an adverse olestra effect.
Cooper
D A
DA
The Procter & Gamble Company, Winton Hill Technical Center, Cincinnati, OH 45224, USA.
Berry
D A
DA
Spendel
V A
VA
Kiorpes
A L
AL
Peters
J C
JC
D015652:25-Hydroxyvitamin D 2 / Q000097:blood; D000824:Animal Nutritional Physiological Phenomena; D000818:Animals; D002112:Calcifediol / Q000097:blood; D004032:Diet; D004042:Dietary Fats, Unsaturated / Q000494:pharmacology*; D002149:Energy Intake; D019358:Fat Substitutes / Q000494:pharmacology*; D005227:Fatty Acids / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008099:Liver / Q000737:chemistry; D008297:Male; D008954:Models, Biological; D011517:Prothrombin Time; D013395:Sucrose / Q000031:analogs & derivatives* / Q000494:pharmacology; D013552:Swine / Q000378:metabolism*; D014801:Vitamin A / Q000032:analysis; D014810:Vitamin E / Q000032:analysis; D014815:Vitamins / Q000493:pharmacokinetics
D004042:Dietary Fats, Unsaturated; D019358:Fat Substitutes; D005227:Fatty Acids; D014815:Vitamins; D014801:Vitamin A; D014810:Vitamin E; D015652:25-Hydroxyvitamin D 2; D013395:Sucrose; C013692:sucrose polyester; D002112:Calcifediol